Update on PARP1 inhibitors in ovarian cancer

Annals of Oncology

Volumn 22, Issue SUPPL.8, 2011, Pages 72-76

  Sessa, C ^a,b  

^a SAN GIOVANNI HOSPITAL   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

DNA repair; Ovarian cancer; PARP; PARP inhibition

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ENZYME INHIBITOR; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; PACLITAXEL; PLACEBO; PLATINUM; POLY(ADENOSINE DIPHOSPHATE RIBOSE)POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER GRADING; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DNA REPAIR; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; ENZYME ACTIVITY; FATIGUE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT INDICATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; DRUG ANTAGONISM; FEMALE; GENETICS; OVARY TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84857383257     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr528     Document Type: Conference Paper

References (19)

1. Rouleau M, Patel A, Hendzel MJ. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10: 293-301.
2. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer 2011; 35: 7-50.
3. Bonner WM, Redon CE, Dickey JS et al. cH2AX and cancer. Nat Rev Cancer 2008; 8: 957-962.
4. Ashworth A. A synthetic lethal therapeutic approach: poly (ADP ribose) polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785-3790.
5. Mendes-Pereira AM, Martin SA, Brough R et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-322.
6. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 1-6.
7. Fong PC, Boss DS, Yap TA et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 1-12.
8. Fong PC, Yap TA, Boss DS et al. Poly (ADP ribose) polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum free interval. J Clin Oncol 2010; 28: 2512-2519.
9. Audeh MW, Carmichael J, Penson RT et al. Oral poly (ADP ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof of concept trial. N Engl J Med 2010; 376: 245-251.
10. Kaye S, Kaufmann B, Lubinsky J et al. Phase II study of the oral PARP inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations. Ann Oncol 2010; 21 (Suppl 8): vii304 (Abstr 3725).
11. Gelmon KA, Hirte HW, Robidoux A et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous cancer and triple negative breast cancer. J Clin Oncol 2010; 28: 18s (Suppl) 233s, (Abstr 3002).
12. Plummer R, Jones C, Middleton M et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor AGO14699 in combination with temozolamide in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 7917-7923.
13. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple negative breast cancer. N Engl J Med 2011; 364: 205-214.
14. Penson RT. A phase II trial of iniparib (BSI201) in combination with gemcitabine/carboplatin (GC) in patients with platinum sensitive recurrent ovarian cancer. J Clin Oncol 2011; 29 (Suppl): 333s (Abstr 5004).
15. Birrer MJ. A phase II trial of iniparib (BSI201) in combination with gemcitabine/carboplatin (GC) in patients with platinum resistant recurrent ovarian cancer. J Clin Oncol 2011; (Suppl): (Abstr 5005).
16. J Lee. A pharmacokinetics/pharmacodynamics study of sequence specificity of the PARP inhibitor olaparib with carboplatin in refractory/recurrent women's cancer: NCT 01237067. J Clin Oncol 2011; (Suppl): 21s (Abstr TPS158).
17. Ledermann JA. Phase II randomized placebo controlled study of olaparib (AZD2281) in patients with platinum sensitive relapsed serous ovarian cancer (PSRSOC). J Clin Oncol 2011; (Suppl): 332s (Abstr 5003).
18. Konstantinopoulos PA, Spentzos D, Karlan BY et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010; 28: 3555-3561.
19. Mukhopadhyay A, Elattar A, Cerbinskaite A et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly (ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010; 16: 2344-2351.